Stock futures in the U.S. are mixed to down slightly, faring better than markets in Europe and Asia, as major averages try to recover from the recent 2-day slide that has pushed major averages lower by 4% during that stretch. Stocks have tumbled the last few sessions following cautious commentary from Fed Chairman Powell, two prominent hedge fund names (Tepper, Druckenmiller), weak CPI and PPI economic data heading into more dubious jobs data today, and concerns from infectious disease expert Fauci, warning about the damage that can be done if economies are opened to quickly. In stock news, shares of Dow component Cisco (CSCO) are higher following better quarterly results overnight and stronger than expected guidance.
In economic data later today, first time unemployment claims are expected at 2.5M, bringing the total of jobless claims over the last 2-months to over 35M. Last week the government said the U.S. unemployment rate surged to a post-World War Two high of 14.7%, or almost 20% if adjusted for furloughs. Geopolitical tensions also weighing on sentiment as the U.S. accused China of trying to steal vaccine information while France objected to one of its drugmakers, Sanofi (SNY), saying it would give U.S. priority to a coronavirus vaccine. In Asian markets, The Nikkei Index dropped -352 points to move back below the 20,000 level at 19,914, the Shanghai Index dropped -27 points to 2,870 and the Hang Seng Index fell -350 points to 23,829. In Europe, the German DAX is lower by nearly -200 points (1.8%) at 10,350, while the FTSE 100 is down over -130 points (2.3%) to 5,765.
Market Closing Prices Yesterday
- The S&P 500 Index plunged -50.12 points, or 1.75%, to 2,820.00
- The Dow Jones Industrial Average fell -516.81 points, or 2.17%, to 23,247.97
- The Nasdaq Composite dropped -139.38 points, or 1.55%, to 8,863.17
- The Russell 2000 Index declined -42.29 points, or 3.32% to 1,233.25
Economic Calendar for Today
- 8:30 AM EST Weekly Jobless Claims…est. 2.5M
- 8:30 AM EST Continuing Claims…est. 25.12M
- 8:30 AM EST Import Prices MoM for April…est. (-3.2%)
- 8:30 AM EST Export Prices MoM for April…est. (-2.3%)
- 10:30 AM EST Weekly EIA Natural Gas Inventory Data
- Earnings Before the Open: ACHV, EQM, IZEA, KEM, SSYS, TRXC, VTNR
- Earnings After the Close: AMAT, BLFS, CVET, DENN, NLOK, VRML
Other Key Events:
- The American Society of Gene & Cell Therapy (ASGCT) 2020 Annual Meeting will be taking place virtually next week 5/12-5/15
- The global case tally for the coronavirus that causes COVID-19 climbed to 4.36 million on Thursday, according to data from by Johns Hopkins University. The death toll rose to 297,465. More than 1.6 million people have recovered. The U.S. has the highest case toll at 1.39 million and the highest death toll at 84,136. Russia has 252,245 cases and 2,305 deaths.
Sector News Breakdown
- Flowers Foods (FLO) Q1 adjusted EPS 41c/$1.349B vs. est. 33c/$1.32B; maintains FY guidance for adj EPS $1.00-1.08 vs. est. $1.06; sees FY capex $95M to $105M, saw $105M to $115M
- Jack in the Box (JACK) Q2 adjusted EPS 50c/$216.16M vs. est. 65c/$210.76M; Q2 system same-store sales decreased (-4.2%), company same-store sales decreased (-4.1%) driven by average check growth of 6.4% while transactions decreased (-10.5%); said system same-store sales increased 5.2% in the seven weeks ended March 8, 2020, prior to any impacts from the COVID-19 pandemic; suspends quarterly cash dividend and share repurchases; restaurant-level margin declined by 700 basis points to 20.6% of sales vs. 27.6% a year ago
- Tyson Foods (TSN) will cut prices for some beef products by 20%-30% in response to surging prices caused by coronavirus outbreaks at meatpacking plants, as per the WSJ. TSN says it will reduce prices for ground beef, roasts and other beef products
- Penske Automotive Group Inc. (PAG) suspended its dividend as of May 13 (was 42c)
- Revolve Group (RVLV) 1Q EPS $0.06 vs. est. $0.04, net sales $146.1Mm vs. est. $139.6Mm; seen trend improvement since mid-Apr, with first ten days of May -25% YoY
Energy, Industrials and Materials
- U.S. Energy Department says it will buy up to 1 mln barrels of sweet crude oil for strategic reserve from small to midsize domestic producers; says oil purchase for SPR will serve as a test of conditions of physical crude oil available to the reserve – Reuters
- The IEA said the world’s demand for crude will drop by 21.5 million barrels a day this month, while crude-producing nations and companies will slash output by 12 million barrels a day.
- 3M Co. (MMM) said monthly sales declines as a result of the COVID-19 pandemic were in line with the trends discussed during the Q1 earnings call on April 28; said April sales fell 11% from a year ago to $2.3 billion. A 5% increase in health care sales was offset by declined of 5% in consumer, 11% in safety and industrial and 20% in transportation and electronics
- Comstock Resources (CRK) 40M share Spot Secondary priced at $5.00
- Mueller Water (MWA) said it took a series of cost saving measures including temporarily shutting down plants and a furlough or salary reduction program for substantially all employees
- Newmont (NEM) said it expects to begin ramping up operations at its Peñasquito mine in Mexico on May 18, following the government’s designation of mining as an essential activity.
- MasterCard (MA) said it sees normalization in some markets, as restrictions ease and consumer spending levels gradually recover from new lows; says services growth will continue to outperform its core products in Q2; says cross-border volume continues to be impacted by decline in travel, but saw modest improvements over the last week in part due to an increase in intra-Europe travel
- A new report from Oxford Economics estimates that 15% of homeowners will fall behind on their monthly mortgage payments. Nearly 4 million homeowners are in the midst of forbearance plans, representing 7.54% of all mortgages, according to the latest data from the Mortgage Bankers Association.
- Allogene Therapeutics (ALLO) shares rise 25%; announced the release of the abstract related to an upcoming oral presentation at the American Society of Clinical Oncology Annual Meeting. This will be the first data from Allogene’s Phase 1 dose escalation study of ALLO-501 in relapsed/refractory non-Hodgkin lymphoma.
- 1Life Healthcare (ONEM) Q1 EPS loss (40c)/$78.8M vs. est. loss (17c)/$75M; said Q1 ending membership count of approximately 455,000, a 25% increase year-over-year; boosts 2020-end membership guidance to 500,000-515,000 from 495,000-510,000; sees Q2 revs $56M-$66M vs. est. $64.3M
- CytomX Therapeutics (CTMX) announces clinical presentations for CX-072 (Abstract 3005), CX-2009 (Abstract 526) as well as CX-2029 (Abstract 3502) developed in partnership with AbbVie (ABBV), to have data cutoff dates of approximately 5-months later than the abstract data cutoff
- Exelixis (EXEL) disclosed in an ASCO abstract that CABOMETYX combination with checkpoint inhibitors has now been active in multiple solid tumors
- Immunic, Inc. (IMUX) shares rise 40%; receives first regulatory approval from German health authority to initiate a phase 2 clinical trial of its selective oral dhodh inhibitor, imu-838
- MacroGenics (MGNX) shares fall -20% after clinical data from two investigational pipeline molecules MGD013 and MGC018; prelim observations from Phase 1 MGD013 trial demonstrated response in ~40% of late-stage HER-2-positive tumors, compared to low response rates for HER-2-directed agents and checkpoint blockade, reported historically.
- SmileDirectClub (SDC) 1Q loss/share 28c vs. est. loss/share 20c on revs $197Mm vs. est. $209.9Mm, 1Q adj EBITDA loss $67Mm vs. est. loss $48.7Mm; says in debt pact with investment partners, to have about $420Mm cash
- Steris (STE) Q4 adj EPS $1.64 on revs $823M (up 7.1% YoY) vs. est. $1.58 and $799.75M; not providing guidance for fiscal 2021
- Tracon Pharmaceuticals (TCON) Q1 EPS loss (78c) vs. est. loss ($1.09); Q1 cash and cash equivalents were $14.1M at March 31, compared to $16.4M at December 31, 2019 and expects current cash and cash equivalents to fund operations into Q1 of 2021; expects Envasarc final clinical trial data in 2022, & provided drug is approved by FDA in 2023
- Ultragenyx (RARE) announces positive longer-term results from first three cohorts of phase 1/2 study of dtx301 gene therapy in ornithine transcarbamylase (otc) deficiency; all three patients in cohort 3 now confirmed responders
- Axcella (AXLA) 11M share Secondary priced at $4.75
- Kiniksa (KNSA) 2.4M share Spot Secondary priced at $18.25
Technology, Media & Telecom
- Cisco Systems (CSCO) Q3 EPS 79c/$11.98 billion (-7.5% YoY) vs. est. 69c/$11.70 billion; 3Q adjusted gross margin 66.6% vs. 64.6% YoY; guides Q4 revs down 8.5%-11.5% vs. est. down (-11.9%) and EPS 72c-74c vs. est. 69c
- Virtusa (VRTU) Q4 adjusted EPS 41c on revs $329.7M vs. est. 56c/$329.6M; says has $300.6M in Cash as of March 31; sees 2021 impacted by Covid-19; remains confident of achieving long-term objectives of greater than industry revenue growth and EPS growth greater than the top-line
- Nvidia Corp. (NVDA) launched its newest line of chips Thursday, detailing artificial-intelligence capabilities up to 20 times greater than previous products, and the new offerings are already working to fight the COVID-19 pandemic.
- Ping Identity (PING) 8.5M share Secondary priced at $24.00
- Intelsat SA (I) shares fall -42% after filing for bankruptcy protection after falling short of the cash it needed to make airwaves available to be sold to wireless operators in a coming government auction; company weighed down by roughly $14.5 billion in debt
Disclosure: The Hammerstone Report
The content of this post was created by the Hammerstone Group. The Hammerstone Institutional Forum, a chat-based platform for traders, provides subscribers with up-to-the-minute breaking news headlines and instant analysis that drive the market. For more information please visit www.thehammerstone.com. For more information on the stocks mentioned in the Hammerstone Recap, please contact Brian Ducey at email@example.com.
Disclosure: Interactive Brokers
Information posted on IBKR Traders’ Insight that is provided by third-parties and not by Interactive Brokers does NOT constitute a recommendation by Interactive Brokers that you should contract for the services of that third party. Third-party participants who contribute to IBKR Traders’ Insight are independent of Interactive Brokers and Interactive Brokers does not make any representations or warranties concerning the services offered, their past or future performance, or the accuracy of the information provided by the third party. Past performance is no guarantee of future results.
This material is from The Hammerstone Report and is being posted with permission from The Hammerstone Report. The views expressed in this material are solely those of the author and/or The Hammerstone Report and IBKR is not endorsing or recommending any investment or trading discussed in the material. This material is not and should not be construed as an offer to sell or the solicitation of an offer to buy any security. To the extent that this material discusses general market activity, industry or sector trends or other broad based economic or political conditions, it should not be construed as research or investment advice. To the extent that it includes references to specific securities, commodities, currencies, or other instruments, those references do not constitute a recommendation to buy, sell or hold such security. This material does not and is not intended to take into account the particular financial conditions, investment objectives or requirements of individual customers. Before acting on this material, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.
There is a substantial risk of loss in foreign exchange trading. The settlement date of foreign exchange trades can vary due to time zone differences and bank holidays. When trading across foreign exchange markets, this may necessitate borrowing funds to settle foreign exchange trades. The interest rate on borrowed funds must be considered when computing the cost of trades across multiple markets.
Disclosure: Futures Trading
Futures are not suitable for all investors. The amount you may lose may be greater than your initial investment. Before trading futures, please read the CFTC Risk Disclosure. A copy and additional information are available at ibkr.com.